Profile data is unavailable for this security.
About the company
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
- Revenue in USD (TTM)0.00
- Net income in USD-8.54m
- Incorporated1994
- Employees17.00
- LocationBioCardia Inc320 Soquel WaySUNNYVALE 94085United StatesUSA
- Phone+1 (650) 226-0123
- Fax+1 (650) 631-3731
- Websitehttps://www.biocardia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 12.06m | 5.00 | -- | 0.6585 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 12.46m | 85.00 | -- | 2.66 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 12.92m | 44.00 | -- | 0.8829 | -- | 114.28 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Curis Inc | 11.65m | -36.56m | 12.93m | 33.00 | -- | -- | -- | 1.11 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 13.07m | 82.00 | -- | 0.3755 | -- | 1.40 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| NewcelX AG | 0.00 | -6.21m | 13.17m | 1.00 | -- | 0.4257 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 13.19m | 11.00 | -- | 1.63 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 13.26m | -- | -- | 0.1488 | -- | 5.25 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| BioCardia Inc | 0.00 | -8.54m | 13.27m | 17.00 | -- | 5.05 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 13.35m | 1.00 | -- | 1.74 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 13.58m | 4.00 | -- | 4.38 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 13.73m | 1.00 | -- | 1.04 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 14.51m | 17.00 | -- | 5.64 | -- | 3.46 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| CM Management LLCas of 31 Dec 2025 | 130.00k | 2.24% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 103.84k | 1.79% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 69.02k | 1.19% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 66.27k | 1.14% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 38.81k | 0.67% |
| Geode Capital Management LLCas of 30 Sep 2025 | 38.74k | 0.67% |
| Brown Advisory LLCas of 30 Sep 2025 | 35.54k | 0.61% |
| Wealth Enhancement Advisory Services LLCas of 31 Dec 2025 | 20.00k | 0.35% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 19.34k | 0.33% |
| Commonwealth Equity Services LLCas of 30 Sep 2025 | 18.28k | 0.32% |
